This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
William Pao, a longtime R&D leader at Roche who briefly held the chief developme...
Jill Wood had pinned her hopes on a little-known federal program to fund her son...
Another day, another molecular glue deal in the biopharma world. This time a...
More than a month after its most recent scheduled meeting was postponed, a panel...
The CDC is looking into a handful of hospitalization cases after people got Ixch...
More than a month after its most recent scheduled meeting was postponed, a panel...
Clinical-stage biotech Mission Therapeutics is closing its preclinical laborator...
John Coster, CMS' senior technical advisor for the Medicare drug rebate and nego...
Verve Therapeutics has not escaped the doom that seems to be engulfing the gene ...
Most healthcare organizations have been using AI for decidedly unglamorous tasks...
Verve Therapeutics has not escaped the doom that seems to be engulfing the gene ...
Teladoc wrapped up its financial year with a $1 billion net loss and disappointi...
Plus, news about Alopexx, Medigene, EpimAb and Belite Bio: Hansoh backs out ...
Something changed for Bill Anderson when he turned 50. He was ascending the rank...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential ne...
Kallyope, a New York City biotech that has raised about $480 million over the pa...